预约演示
更新于：2025-02-20
Empagliflozin
恩格列净
更新于：2025-02-20
概要
基本信息
药物类型 小分子化药 |
别名 Empagliflozin (JAN/USAN/INN)、Oboravo、依帕列净 + [10] |
靶点 |
作用机制 SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H27ClO7 |
InChIKeyOBWASQILIWPZMG-QZMOQZSNSA-N |
CAS号864070-44-0 |
关联
695
项与 恩格列净 相关的临床试验TCTR20241215007
A Bioequivalence study of a randomized, single dose, two-way crossover design with two-period, two-treatment and two-sequence of EMPAGLINAZ 25 (Empagliflozin Tablets 25 mg) relative to JARDIANCE film-coated tablets 25 mg in healthy Thai adult volunteers under fasting condition
NCT03867487
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
NCT06653738
Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial
100 项与 恩格列净 相关的临床结果
登录后查看更多信息
100 项与 恩格列净 相关的转化医学
登录后查看更多信息
100 项与 恩格列净 相关的专利（医药）
登录后查看更多信息
4,146
项与 恩格列净 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-utility analysis of empagliflozin for heart failure in the Philippines
Article
作者: Llanes, Elmer Jasper ; Salvador, Dante ; Añonuevo, John ; Montilla, Precious Juzenda ; Ong-Garcia, Helen ; Encarnacion, Patrick James ; Taneo, Mary Joy ; Orolfo, Diana Dalisay ; Aquino, Camilo Oliver ; Villanueva, Anthony Russell ; Cunanan, Elaine ; Permejo, Chito
AIMS:
Empagliflozin confers cardioprotective benefits among patients with heart failure, across the range of ejection fraction (EF), regardless of type 2 diabetes status. The long-term cost-effectiveness of empagliflozin for the treatment of heart failure (HF) in the Philippines remains unclear. This study aims to determine the economic benefit of adding empagliflozin to the standard of care (SoC) vs the SoC alone for HF in the Philippines.
METHODS:
Using a Markov model, we predicted lifetime costs and clinical outcomes associated with treating HF in the Philippine setting. We used estimates of treatment efficacy, event probabilities, and derivations of utilities from the EMPEROR trials. Costs were derived from hospital tariffs and expert consensus. Separate analyses were performed for patients with left ventricular EF > 40%, categorized under mid-range ejection fraction or preserved ejection fraction (HFmrEF/HFpEF), and patients with left EF ≤ 40%, categorized under HF with reduced ejection fraction (HFrEF).
RESULTS:
Our model predicted an average of 0.09 quality-adjusted life year (QALY) gains among HFmrEF/HFpEF patients and HFrEF patients when empagliflozin was compared to SoC. The addition of empagliflozin in the treatment results in a discounted incremental lifetime cost of PHP 62,692 (USD 1,129.99) and PHP 17,215 (USD 308.67) for HFmrEF/HFpEF and HFrEF, respectively. The incremental cost-effectiveness ratio (ICER) of empagliflozin is PHP 198,270 (USD 3,570.72)/QALY and PHP 742,604 (USD 13,385.08)/QALY for HFrEF and HFmrEF/HFpEF, respectively.
LIMITATIONS:
This study employed parameters derived from short-term clinical trial data, alongside metrics representative of Asian populations, which are not specific to the Philippine cohort.
CONCLUSIONS:
Adding empagliflozin to the SoC in comparison to the SoC is associated with improved clinical outcomes and quality-of-life, at additional costs for both HFrEF and HFmrEF/HFpEF.
2025-12-01MOLECULAR BIOLOGY REPORTS
Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
Review
作者: Bhatti, Jasvinder Singh ; Kaur, Maninder ; Navik, Umashanker ; Rawat, Pushkar Singh ; Jaiswal, Aiswarya ; Yadav, Poonam ; Babu, Srivalliputturu Sarath ; Khurana, Amit
Diabetic cardiomyopathy (DCM) represents a significant health burden, exacerbated by the global increase in type 2 diabetes mellitus (T2DM). This condition contributes substantially to the morbidity and mortality associated with diabetes, primarily through myocardial dysfunction independent of coronary artery disease. Current treatment strategies focus on managing symptoms rather than targeting the underlying pathophysiological mechanisms, highlighting a critical need for specific therapeutic interventions. This review explores the multifaceted role of empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, in addressing the complex etiology of DCM. We discuss the key mechanisms by which hyperglycemia contributes to cardiac dysfunction, including oxidative stress, mitochondrial impairment, and inflammation, and how empagliflozin mitigates these effects. Empagliflozin's effects on reducing hospitalization for heart failure and potentially lowering cardiovascular mortality mark it as a promising candidate for DCM management. By elucidating the underlying mechanisms through which empagliflozin operates, this review underscores its therapeutic potential and paves the way for future research into its broader applications in diabetic cardiac care. This synthesis aims to foster a deeper understanding of DCM and encourage the integration of empagliflozin into treatment paradigms, offering hope for improved outcomes in patients suffering from this debilitating condition.
2025-06-01IBRO Neuroscience Reports
Neuroprotective effects of empagliflozin against scopolamine-induced memory impairment and oxidative stress in rats
Article
作者: Hosseini, Mir-Jamal ; Anoush, Mahdieh ; Bijani, Soroush ; Taghaddosi, Neda ; Bokaei Hosseini, Zahra ; Rahmati, Fatemeh ; Kalantari-Hesari, Ali
Alzheimer's disease (AD) is one of the most common age-related neurodegenerative disorders. The main medicinal theory for the management of AD belongs to the acetyl-cholinesterase-inhibition pathway and NMDA antagonism. Recent investigation proposed memory improvement by sodium-glucose co-transporter 2 (SGLT2) inhibitors which indicated to improve glycemic control in adults with type 2 diabetes mellitus. According to the lack of sufficient evidence about the efficacy of empagliflozin (EMPA) for memory improvement, in comparison with donepezil (DON), the present research was carried out in order to investigate this hypothesis towards scopolamine-induced neurotoxicity on experimental male Wistar rats. The animals divided into two sets, each included 4 groups: The first set of Healthy animals [Control, EMPA (4 or 10 mg/kg), DON (1 mg/kg)]. The second set of rat Alzheimer model, which received 2 mg/kg Scopolamine by intraperitoneal route for 10 days followed by other treatments [AD, AD+ EMPA (4 or 10 mg/kg) and AD+DON]. Normal rats and AD rats, with each group receiving different substances for 8 consecutive days and 24 h after the accomplishment of the drug administrations, the memory functions assessed through Morris water maze (MWM) paradigm. This task was followed by decapitation of rats in order to evaluate the biochemical oxidative stress parameters in brain tissue. Our data indicated that EMPA significantly improved animals' performance in the behavioral test with a significant decrease in oxidative stress and antioxidant imbalance. In addition, EMPA (4 mg/kg) significantly reduced both cellular malondialdehyde and protein carbonyl content while conversely increased the total reduced glutathione content. Besides, the levels of total as well as endogenous antioxidants in the ferric reducing antioxidant power assay reported to be augmented. It seems that EMPA significantly improved both cellular biochemical aspects and memory performance in animal models in accordance with histopathological assessments. Conclusively, 4 mg/kg EMPA demonstrated better results in all aspects that were evaluated during this research.
100 项与 恩格列净 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 中国 | 2023-05-26 | |
| 心血管疾病 | 中国 | 2023-05-26 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数保留型心力衰竭 | 中国 | 2022-08-30 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 射血分数降低的心力衰竭 | 中国 | 2022-06-10 | |
| 慢性心力衰竭 | 欧盟 | 2014-05-22 | |
| 慢性心力衰竭 | 冰岛 | 2014-05-22 | |
| 慢性心力衰竭 | 列支敦士登 | 2014-05-22 | |
| 慢性心力衰竭 | 挪威 | 2014-05-22 | |
| 慢性肾病 | 澳大利亚 | 2014-04-30 | |
| 2型糖尿病 | 澳大利亚 | 2014-04-30 | |
| 心脏衰竭 | 澳大利亚 | 2014-04-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 墨西哥 | 2023-02-06 | |
| 肾性糖尿 | 临床3期 | - | 2023-01-01 | |
| 精神分裂症 | 临床3期 | - | 2023-01-01 | |
| 非酒精性脂肪性肝炎 | 临床3期 | 埃及 | 2022-11-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2022-03-11 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2020-12-16 | |
| 急性心肌梗塞 | 临床3期 | 中国 | 2020-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 105 | 製廠繭遞膚鹹構衊願襯(願鹽觸艱積窪鑰構鏇夢) = 鹽夢獵積築繭範鹹鬱膚 淵鑰廠觸製築齋鬱廠繭 (餘鏇鑰淵蓋鹹壓鹽構鹹, 2.5) | 积极 | 2025-01-10 | |||
Placebo | - | ||||||
临床3期 | 6,522 | Placebo (Placebo) | 獵淵網齋衊壓壓憲鹽壓(製網觸網繭範製鏇衊觸) = 糧積築膚醖構製鬱製蓋 廠廠觸鹽壓獵蓋選積積 (醖鏇構獵繭醖遞願蓋糧, 觸鑰鬱艱餘壓膚鏇憲網 ~ 夢糧選艱糧選願遞鬱廠) 更多 | - | 2025-01-07 | ||
(Empagliflozin 10 mg) | 獵淵網齋衊壓壓憲鹽壓(製網觸網繭範製鏇衊觸) = 糧繭鹹鏇齋鹽膚夢糧糧 廠廠觸鹽壓獵蓋選積積 (醖鏇構獵繭醖遞願蓋糧, 艱選廠網衊蓋願積築蓋 ~ 鑰窪鏇壓夢觸壓艱艱願) 更多 | ||||||
临床3期 | 慢性肾病 estimated glomerular filtration rate (eGFR) | urinary albumin-to-creatinine ratio | 6,609 | 膚願願鏇廠築淵齋獵膚(醖網鹽鏇襯觸餘獵範鬱) = 繭構築範觸憲簾願製壓 積壓願餘簾鬱醖衊觸衊 (鑰觸鑰鏇鬱顧廠觸繭鹹 ) 更多 | 积极 | 2024-10-25 | ||
Placebo | 膚願願鏇廠築淵齋獵膚(醖網鹽鏇襯觸餘獵範鬱) = 顧獵壓觸醖遞製艱鹽網 積壓願餘簾鬱醖衊觸衊 (鑰觸鑰鏇鬱顧廠觸繭鹹 ) 更多 | ||||||
临床3期 | 313 | 繭鹹願齋遞鬱鹹衊廠壓(壓壓網鑰繭淵糧鬱遞鑰) = parameters for diastolic function showed a distinct trend between groups but did not meet statistical significance in this cohort 鬱膚鹹蓋獵獵艱積繭壓 (繭構遞襯範顧膚鏇鹹餘 ) 更多 | 积极 | 2024-09-16 | |||
Placebo | |||||||
临床3期 | - | 製簾網鏇顧壓襯範鏇窪(鬱衊鹽廠糧艱積顧觸製) = 淵淵獵窪鹹醖膚醖積襯 壓衊衊鬱憲鑰廠觸願顧 (鏇繭糧襯蓋鑰繭蓋鏇網 ) | 积极 | 2024-09-09 | |||
Placebo | 製簾網鏇顧壓襯範鏇窪(鬱衊鹽廠糧艱積顧觸製) = 艱簾鏇簾觸獵蓋獵鬱選 壓衊衊鬱憲鑰廠觸願顧 (鏇繭糧襯蓋鑰繭蓋鏇網 ) | ||||||
N/A | - | - | 觸鹽餘鏇鏇顧餘願網壓(遞齋繭餘壓繭糧構選範) = 13.3% experiencing mostly Level 1 hypoglycemia 襯鹹窪鹹鹹淵願壓顧糧 (廠淵衊繭積製遞選獵夢 ) 更多 | - | 2024-09-02 | ||
N/A | - | - | 憲遞繭鑰鹽艱選廠觸蓋(淵積鏇觸願憲糧選鏇壓) = 夢網廠醖鬱鹽憲蓋淵願 鏇夢積鏇網鹽餘膚餘襯 (餘鹹憲鹹遞簾艱蓋選顧, 6) | - | 2024-09-02 | ||
N/A | - | 遞選衊蓋夢製獵積壓夢(憲窪鬱夢膚繭夢憲糧積) = 鏇蓋夢衊鹽網鹽鹹憲製 窪醖鹽齋醖構製襯憲觸 (齋窪顧窪夢觸膚築襯淵 ) 更多 | - | 2024-09-01 | |||
Placebo | 遞選衊蓋夢製獵積壓夢(憲窪鬱夢膚繭夢憲糧積) = 膚鹹積願鏇簾廠鏇淵築 窪醖鹽齋醖構製襯憲觸 (齋窪顧窪夢觸膚築襯淵 ) 更多 | ||||||
N/A | - | 齋鹽選壓憲蓋顧網淵選(艱鑰醖糧餘遞觸鹹糧襯) = 窪構鹹築選衊製構願餘 鏇壓憲遞衊窪艱糧夢遞 (網積齋鹹獵鹹顧廠積積 ) 更多 | - | 2024-09-01 | |||
Standard medical therapy | 齋鹽選壓憲蓋顧網淵選(艱鑰醖糧餘遞觸鹹糧襯) = 壓獵網窪淵鏇願膚製齋 鏇壓憲遞衊窪艱糧夢遞 (網積齋鹹獵鹹顧廠積積 ) 更多 | ||||||
N/A | 心脏衰竭 NT-proBNP levels | 450 | 積醖選餘憲窪顧築築憲(齋膚遞餘憲廠鏇壓簾廠) = showed a more substantial decrease in the Empagliflozin group compared to the placebo 遞範淵襯築築鑰艱鹹繭 (簾築鬱製壓夢顧遞壓蓋 ) 更多 | 积极 | 2024-08-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用